<DOC>
	<DOCNO>NCT02013687</DOCNO>
	<brief_summary>This study Phase 1 , dose escalation , first-in-human study design primarily evaluate safety purify plant-derived Pfs25 VLP combine Alhydrogel adjuvant</brief_summary>
	<brief_title>Safety Immunogenicity Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male nonpregnant , nonlactating female age 18 50 year inclusive Able give write informed consent obtain prior screen Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination baseline Women childbearing potential must negative urine pregnancy test within 24 hour precede receipt dose . Females fulfill one follow criterion : 1 . At least one year postmenopausal 2 . Surgically sterile 3 . Willing use oral , implantable , transdermal injectable contraceptive 30 day prior first vaccination study duration 4 . Willing abstain sexual intercourse use another reliable form contraception approve Investigator ( e.g. , intrauterine device ( IUD ) , female condom , diaphragm spermicide , cervical cap , use condom sexual partner sterile sexual partner ) 30 day prior first vaccination 9 month third vaccination Comprehension study requirement , demonstrate achieve score least 80 % correct short multiplechoice quiz . Individuals fail achieve pass score initial comprehension assessment give opportunity retest review protocol information . Individuals fail comprehension assessment second time enrol . Available able participate plan study visit procedure . History malaria previous receipt investigational malaria vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>